Impact of liposomal amphotericin B therapy on chronic pulmonary aspergillosis
详细信息 查看全文
- 作者：Pippa J. Newtona ; pippa.newton@uhsm.nhs.uk" class="auth_mail" title="E-mail the corresponding author ; pippanewton@nhs.net" class="auth_mail" title="E-mail the corresponding author ; Chris Harrisa ; Julie Morrisb ; David W. Denninga
- 关键词：Liposomal amphotericin B ; Chronic pulmonary aspergillosis ; Aspergillus ; Acute kidney injury ; Quality of life
- 刊名：Journal of Infection
- 出版年：2016
- 出版时间：November 2016
- 年：2016
- 卷：73
- 期：5
- 页码：485-495
- 全文大小：692 K
文摘
- bel">•
Clinical response to the first LAmB course in CPA patients was 74%.
- bel">•
Improvements in QOL in CPA patients after their first LAmB course was 92%.
- bel">•
50% of CPA patients had an increased risk of AKI with their first LAmB course.
- bel">•
25% of CPA patients developed AKI with their first LAmB course.
- bel">•
The geometric mean eGFR in CPA patients was reduced post LAmB therapy.